Roche Half-Year Report 2023

• Excluding COVID-19 products, Group sales increase strongly by 8%¹ at constant exchange rates (CER)
• In line with the expected declining demand for COVID-19 products, Group sales decrease 2% (-8% in Swiss francs)
• Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driver
• Diagnostics Division’s base business continues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022
• Core earnings per share decrease 5%, driven by lower demand for COVID-19 products and a base effect from a patent settlement in 2022; IFRS net income down 9% due to lower core operating profit and higher interest expenses

Highlights in the second quarter of 2023:

• • US and EU approvals of Columvi (aggressive form of blood cancer)
  • US approval of Elevidys for Roche partner Sarepta (first gene therapy for children with Duchenne muscular dystrophy)
  • Positive phase III data for subcutaneous injection of Ocrevus (multiple sclerosis); positive long-term efficacy and safety data for Evrysdi (spinal muscular atrophy) and positive phase II data for fenebrutinib (multiple sclerosis)
  • Start of phase III study of tiragolumab in combination with Tecentriq and Avastin (liver cancer)
  • Partnership with Alnylam to co-develop phase II RNAi therapeutic zilebesiran (hypertension in patients with high cardiovascular risk)
  • WHO prequalification of cobas HPV test enables improved access to cervical cancer screening in low and lower-middle income countries